Scarica l'app Stockscreener
67.24
3.54%
2.30
Precedente Chiudi:
$64.94
Aprire:
$65.67
Volume 24 ore:
1.18M
Relative Volume:
0.44
Capitalizzazione di mercato:
$13.14B
Reddito:
$579.96M
Utile/perdita netta:
$-729.89M
Rapporto P/E:
-17.95
EPS:
-3.7459
Flusso di cassa netto:
$-452.02M
1 W Prestazione:
+3.38%
1M Prestazione:
-1.68%
6M Prestazione:
-13.46%
1 anno Prestazione:
+18.74%
Intervallo 1D:
$65.44
$67.48
Intervallo di 1 settimana:
$62.86
$66.42
Portata 52W:
$52.75
$93.42
Bridgebio Pharma Inc Stock (BBIO) Company Profile
Nome
Bridgebio Pharma Inc
Settore
Industria
Telefono
(650) 391-9740
Indirizzo
3160 PORTER DR., PALO ALTO, CA
Compare BBIO vs VRTX, MRNA, REGN, ARGX, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
BBIO
Bridgebio Pharma Inc
|
67.24 | 13.14B | 579.96M | -729.89M | -452.02M | -3.7459 |
VRTX
Vertex Pharmaceuticals Inc
|
509.10 | 129.04B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
238.23 | 95.11B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
800.96 | 82.46B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
847.89 | 53.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
371.80 | 42.06B | 5.76B | 514.49M | 1.10B | 4.4813 |
Bridgebio Pharma Inc Stock (BBIO) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-06-03 | Iniziato | Canaccord Genuity | Buy |
| 2026-05-26 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2026-05-19 | Iniziato | Citigroup | Neutral |
| 2026-04-09 | Iniziato | RBC Capital Mkts | Outperform |
| 2026-03-10 | Iniziato | William Blair | Outperform |
| 2026-01-28 | Iniziato | Barclays | Overweight |
| 2026-01-06 | Iniziato | Morgan Stanley | Overweight |
| 2025-12-11 | Iniziato | Bernstein | Outperform |
| 2025-07-30 | Ripresa | Raymond James | Outperform |
| 2025-07-21 | Iniziato | Truist | Buy |
| 2025-07-14 | Iniziato | Jefferies | Buy |
| 2025-07-09 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2025-06-17 | Iniziato | Wolfe Research | Outperform |
| 2025-03-31 | Iniziato | Redburn Atlantic | Buy |
| 2024-10-16 | Iniziato | Scotiabank | Sector Outperform |
| 2024-10-03 | Iniziato | Oppenheimer | Perform |
| 2024-09-04 | Iniziato | Piper Sandler | Overweight |
| 2024-03-21 | Ripresa | Raymond James | Outperform |
| 2024-01-31 | Iniziato | BMO Capital Markets | Market Perform |
| 2023-12-08 | Iniziato | Wells Fargo | Overweight |
| 2023-11-07 | Iniziato | Citigroup | Buy |
| 2023-10-24 | Iniziato | Cantor Fitzgerald | Overweight |
| 2023-07-18 | Downgrade | Jefferies | Buy → Hold |
| 2023-04-19 | Iniziato | Evercore ISI | Outperform |
| 2023-02-06 | Iniziato | Cowen | Outperform |
| 2021-12-27 | Reiterato | Mizuho | Buy |
| 2021-12-27 | Reiterato | SVB Leerink | Outperform |
| 2021-09-10 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2021-05-21 | Iniziato | UBS | Buy |
| 2021-03-22 | Reiterato | Goldman | Buy |
| 2021-02-22 | Ripresa | JP Morgan | Overweight |
| 2021-02-09 | Ripresa | Goldman | Buy |
| 2021-01-11 | Reiterato | H.C. Wainwright | Buy |
| 2020-12-10 | Reiterato | H.C. Wainwright | Buy |
| 2020-06-25 | Iniziato | BofA/Merrill | Neutral |
| 2020-05-19 | Iniziato | BTIG Research | Buy |
| 2020-04-13 | Iniziato | H.C. Wainwright | Buy |
| 2020-02-19 | Iniziato | Mizuho | Buy |
| 2019-07-26 | Iniziato | Raymond James | Outperform |
| 2019-07-22 | Iniziato | BMO Capital Markets | Outperform |
| 2019-07-22 | Iniziato | Goldman | Buy |
| 2019-07-22 | Iniziato | JP Morgan | Overweight |
| 2019-07-22 | Iniziato | Jefferies | Buy |
| 2019-07-22 | Iniziato | Piper Jaffray | Overweight |
| 2019-07-22 | Iniziato | SVB Leerink | Outperform |
Mostra tutto
Bridgebio Pharma Inc Borsa (BBIO) Ultime notizie
Acoramidis Associated with Significantly Improved Clinical Outcomes Versus Tafamidis in ATTR-CM in an Independent, Real-World Study of U.S. Electronic Health Records - GlobeNewswire Inc.
Encaleret Increased Bone Turnover and Improved Participant-Reported Symptoms in the Phase 3 CALIBRATE Trial in ADH1 - GlobeNewswire Inc.
FDA Grants Priority Review to BridgeBio's Dwarfism Drug Filing - Zacks Investment Research
BridgeBio Pharma CEO Neil Kumar sells $690,847 in shares - Investing.com
BridgeBio Pharma CEO Neil Kumar sells $690,847 in shares By Investing.com - Investing.com Nigeria
BridgeBio (NASDAQ: BBIO) CEO’s trust sells 10,000 shares under preset plan - Stock Titan
BridgeBio Pharma stock gains attention as fresh inducement grants highlight growth plans - AD HOC NEWS
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
133,900 Preferred Stock of BridgeBio Pharma, Inc. are subject to a Lock-Up Agreement Ending on 13-SEP-2026. - marketscreener.com
Bio-Rad Laboratories, Inc. at Wells Fargo Healthcare Conference Transcript - GuruFocus
Analysts Offer Insights on Healthcare Companies: BridgeBio Pharma (BBIO), EyePoint Pharmaceuticals (EYPT) and Abbott Laboratories (ABT) - The Globe and Mail
H.C. Wainwright Maintains BridgeBio Pharma(BBIO.US) With Buy Rating, Maintains Target Price $120 - Moomoo
BIO-RAD LABORATORIES (NYSE: BIO) Grants 719 Derivative Securities to Director Allison Schwartz - Kalkine Media
BridgeBio at Cantor global healthcare conference: launch pipeline in focus By Investing.com - Investing.com Nigeria
BIO-RAD LABORATORIES Executive Evran Sedat Reports Exercising 3,880 Shares (NYSE: BIO) - Kalkine Media
BridgeBio at Cantor global healthcare conference: launch pipeline in focus By Investing.com - Investing.com Canada
Bio-Rad: Favorable Read-Across From Investor Event (NYSE:BIO) - Seeking Alpha
BBIO Reiterated by HC Wainwright & Co. -- Rating Maintained at B - GuruFocus
BridgeBio Pharma: Attruby Peak Sales Set To Rise - Seeking Alpha
H.C. Wainwright reiterates BridgeBio Pharma stock rating at buy By Investing.com - Investing.com India
H.C. Wainwright reiterates BridgeBio Pharma stock rating at buy By Investing.com - Investing.com Canada
Bio-Rad (NYSE: BIO) director sees 320 RSUs convert, 116 shares withheld - Stock Titan
[Form 4] BIO-RAD LABORATORIES, INC. Insider Trading Activity - Stock Titan
Bio-Rad (NYSE: BIO) EVP logs 4,313 RSU grant and 2,179 vested shares - Stock Titan
[Form 4] BIO-RAD LABORATORIES, INC. Insider Trading Activity - Stock Titan
1,453 stock units vest for Bio-Rad (NYSE: BIO) insider as 551 shares withheld - Stock Titan
Bio-Rad (NYSE: BIO) grants EVP 4,601 RSUs, with shares withheld at $386.11 - Stock Titan
[Form 4] BIO-RAD LABORATORIES, INC. Insider Trading Activity - Stock Titan
Bio-Rad at Wells Fargo conference: margin push takes center stage - Investing.com Canada
Bio-Rad at Wells Fargo conference: margin push takes center stage - Investing.com India
Bio-Rad at Wells Fargo conference: margin push takes center stage - Investing.com UK
BridgeBio at Wells Fargo conference: growth plan centers on 2027 launches - Investing.com India
Bio-Rad Terminates Forbes Tate Lobbying Pact - Legis1
BBIO: Multiple late-stage therapies targeting rare genetic diseases set for US launches by 2027 - TradingView
Why (BBIO) Price Action Is Critical for Tactical Trading - Stock Traders Daily
BridgeBio Pharma (BBIO) Down 10.7% Since Last Earnings Report: Can It Rebound? - Yahoo Finance
BridgeBio Dwarfism Data Shows Broad Health Benefits Beyond Height Gain - Benzinga
BridgeBio reports Phase 3 infigratinib achondroplasia data - grafa.com
BridgeBio Oncology Therapeutics, Inc. SEC Filing (Sep 9, 2026) - stocktitan.net
13 Red Days In A Row: BridgeBio Pharma Stock Is Down 11% - Trefis
BridgeBio’s infigratinib shows improvements in achondroplasia study By Investing.com - Investing.com Nigeria
BBIO Looks 51.2% Undervalued on GF Value™ Despite Profitability Challenges - GuruFocus
BridgeBio’s infigratinib shows improvements in achondroplasia study By Investing.com - Investing.com Canada
BridgeBio’s infigratinib shows improvements in achondroplasia study - investing.com
Achondroplasia Market Analysis Report 2026: Emerging Pipeline Intensifies Competition, Featuring Ascendis Pharma, BioMarin Pharmaceutical, QED Therapeutics (BridgeBio), Novartis, Kyowa Kirin, RIBOMIC - Yahoo Finance
BridgeBio Pharma Reports Favorable Exploratory PROPEL 3 Data for Oral Infigratinib in Achondroplasia, Including Sleep Apnea and Ear Infection Trends - Quiver Quantitative
BridgeBio’s infigratinib shows improvements in achondroplasia study By Investing.com - Investing.com UK
A sleep-apnea measure rose 10.4% with an experimental drug, versus 49.2% with placebo - Stock Titan
Bio-Rad expands range of Foresight prepacked chromatography columns for biomanufacturing - selectscience.net
Bridgebio Pharma Inc Azioni (BBIO) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Bridgebio Pharma Inc Azioni (BBIO) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| KUMAR HALDEA FAMILY IRREVOCABL | Director |
Aug 19 '26 |
Proposed Sale |
82.98 |
30,000 |
2,489,400 |
0 |
| Kumar Neil | Chief Executive Officer |
Aug 19 '26 |
Sale |
84.03 |
10,000 |
840,257 |
505,686 |
| Kumar Neil | Chief Executive Officer |
Aug 18 '26 |
Sale |
82.53 |
34,980 |
2,886,994 |
243,327 |
| NEIL KUMAR | Director |
Aug 18 '26 |
Proposed Sale |
79.89 |
34,980 |
2,794,552 |
0 |
| RANDAL SCOTT | Director |
Aug 17 '26 |
Proposed Sale |
79.86 |
21,501 |
1,717,070 |
0 |
| Apuli Maricel | Chief Accounting Officer |
Jul 30 '26 |
Sale |
80.06 |
2,000 |
160,120 |
127,401 |
| Ellis Andrea | Director |
Jul 09 '26 |
Option Exercise |
16.75 |
17,167 |
287,547 |
39,746 |
| ANDREA ELLIS | Director |
Jul 09 '26 |
Proposed Sale |
84.00 |
17,167 |
1,442,028 |
0 |
| JENNIFER COOK | Director |
Jul 09 '26 |
Proposed Sale |
88.54 |
148,589 |
13,156,008 |
0 |
| Cook Jennifer E. | Director |
Jul 09 '26 |
Sale |
88.54 |
148,589 |
13,156,008 |
8,383 |
3.83%
2.28%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):